206 related articles for article (PubMed ID: 38617746)
1. Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope.
Giri S; Sahoo J
World J Gastroenterol; 2024 Mar; 30(12):1670-1675. PubMed ID: 38617746
[TBL] [Abstract][Full Text] [Related]
2. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
Desai KK; Khan MS; Toumpanakis C; Caplin ME
Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
[TBL] [Abstract][Full Text] [Related]
3. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
4. Advances in understanding and management of high-grade pancreatic neuroendocrine neoplasm: a comprehensive review.
Regalla DKR; Deep O; Paluri RK
Chin Clin Oncol; 2023 Dec; 12(6):67. PubMed ID: 38073310
[TBL] [Abstract][Full Text] [Related]
5. The evolving landscape of neuroendocrine tumors.
Bergsland EK
Semin Oncol; 2013 Feb; 40(1):4-22. PubMed ID: 23391109
[TBL] [Abstract][Full Text] [Related]
6. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors.
Vitali E; Piccini S; Trivellin G; Smiroldo V; Lavezzi E; Zerbi A; Pepe G; Lania AG
Mol Cell Endocrinol; 2021 May; 527():111226. PubMed ID: 33675866
[TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
Dasari A; Bergsland EK; Benson AB; Cai B; Huynh L; Totev T; Shea J; Duh MS; Neary MP; Dagohoy CG; Shih BE; Maurer VE; Chan J; Kulke MH
Oncologist; 2019 Aug; 24(8):1066-1075. PubMed ID: 30610008
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.
Ruggeri RM; Benevento E; De Cicco F; Fazzalari B; Guadagno E; Hasballa I; Tarsitano MG; Isidori AM; Colao A; Faggiano A;
J Endocrinol Invest; 2023 Feb; 46(2):213-234. PubMed ID: 36038743
[TBL] [Abstract][Full Text] [Related]
9. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
Chan JA; Kulke MH
Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
[TBL] [Abstract][Full Text] [Related]
10. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
Hauser H; Gerson DS; Reidy-Lagunes D; Raj N
Curr Treat Options Oncol; 2019 Nov; 20(12):87. PubMed ID: 31776785
[TBL] [Abstract][Full Text] [Related]
11. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors.
Halperin DM; Kulke MH; Yao JC
Annu Rev Med; 2015; 66():1-16. PubMed ID: 25341008
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms.
Mosalem O; Sonbol MB; Halfdanarson TR; Starr JS
Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101796. PubMed ID: 37414652
[TBL] [Abstract][Full Text] [Related]
13. Therapy Sequencing in Patients With Advanced Neuroendocrine Neoplasms.
Riechelmann RP; Taboada RG; de Jesus VHF; Iglesia M; Trikalinos NA
Am Soc Clin Oncol Educ Book; 2023 May; 43():e389278. PubMed ID: 37257140
[TBL] [Abstract][Full Text] [Related]
14. Update in the Therapy of Advanced Neuroendocrine Tumors.
Uri I; Avniel-Polak S; Gross DJ; Grozinsky-Glasberg S
Curr Treat Options Oncol; 2017 Nov; 18(12):72. PubMed ID: 29143892
[TBL] [Abstract][Full Text] [Related]
15. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK
J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329
[TBL] [Abstract][Full Text] [Related]
16. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
Pasricha G; Padhi P; Daboul N; Monga DK
Clin Ther; 2017 Nov; 39(11):2146-2157. PubMed ID: 29173655
[TBL] [Abstract][Full Text] [Related]
17. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.
Pusceddu S; De Braud F; Festinese F; Bregant C; Lorenzoni A; Maccauro M; Milione M; Concas L; Formisano B; Leuzzi L; Mazzaferro V; Buzzoni R
Future Oncol; 2015; 11(13):1947-59. PubMed ID: 26161929
[TBL] [Abstract][Full Text] [Related]
18. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Phan AT; Kunz PL; Reidy-Lagunes DL
Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
[TBL] [Abstract][Full Text] [Related]
19. Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.
Castellano D; Grande E; Valle J; Capdevila J; Reidy-Lagunes D; O'Connor JM; Raymond E
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1099-114. PubMed ID: 25480314
[TBL] [Abstract][Full Text] [Related]
20. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]